Update in the treatment of type 2 diabetes mellitus. The α-elucosidase inhibitors;Actualités dans les traitements du diabète de type 2. Les inhibiteurs des alpha-glucosidases

Revue de Medecine Interne

Volumn 20, Issue SUPPL. 3, 1999, Pages 379-383

  Blickle J F ^a   Andres, E ^b   Brogard, J M ^a  

^a HÔPITAL CIVIL   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

glucosidase inhibitors; Postprandial glycaemia; Type 2 diabetes mellitus

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; DISACCHARIDE; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOSAMINE; IMINOSUGAR; INSULIN; MIGLITOL; POLYSACCHARIDE;

CARBOHYDRATE DIET; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; HYDROLYSIS; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ACARBOSE; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; DISACCHARIDES; DRUG COMBINATIONS; ENZYME INHIBITORS; GLUCOSAMINE; HUMANS; HYDROLYSIS; HYPOGLYCEMIC AGENTS; IMINO PYRANOSES; INSULIN; POLYSACCHARIDES;

EID: 0033170483     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 ; 352 : 837-53.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998 ; 352 : 854-65.
3. Taylor RH. Alpha-glucosidase inhibitors. In : Bailey CJ, Flatt PR, eds. New antidiabetic drugs. London : Smith Gordon ; 1990. p. 119-32.
4. Fujimoto Y, Ohhira M, Miyokawa N, Kitamori S, Kohgo Y. Acarbose-induced hepatic injury. Lancet 1998 ; 351 : 340.
5. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W. Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneim-Forsch Drug Res 1997 ; 47 : 734-45.
6. Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? Br J Clin Pharmacol 1990 ; 30 : 391-6.
7. Sels JPJE, Nauta JJP, Menheere PPCA, Wolffenbuttel BHR, Nieuwenhuijzen-Kruseman AC. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. Br J Clin Pharmacol 1996 ; 42 : 503-6.
8. Reuser AJJ, Wisselaar HA. An evaluation of the potential side-effects of α-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 1994 ; 24 : 19-24.
9. Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 1996 ; 45 : 731-7.
10. Kageyama S, Nakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther 1997 ; 19 : 720-9.
11. Kawagishi T, Nishizawa Y, Taniwaki H, Tanaka S, Okundo Y, Inaba M, et al. Relationship between gastric emptying and an α-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients. Diabetes Care 1997 ; 20 : 1529.
12. Lebovitz HE. α-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998 ; 2 : 132-45.
13. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996 ; 19 : 1190.
14. Jenny A, Proietto J, O'Dea K, Nankervis A, Trainedes K, D'Embden H. Low dose acarbose improves glycaemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care 1993 ; 16 : 499-502.
15. Johnson AB, Taylor R. Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Diabetes Care 1996 ; 19 : 559-63.
16. Schnack C, Prager RJF, Winkler J, Klauser RM, Schneider BG, Schernthaner G. Effect of 8-wk α-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 1989 ; 12 : 537-43.
17. Matsumoto K, Yano M, Miyake S, Ueki Y, Yamaguchi Y, Akazawa S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998 ; 21 : 256-60.
18. Goke B, Fuder H, Wieckhorst G, Theiss U, Stridde E, Littke T, et al. Voglibose (AO-128) is an efficient alpha-glucosidase inhibitor and mobilizes the endogenous GLP-1 reserve. Digestion 1995 ; 56 : 493-501.
19. Scheen A. Clinical efficacy of acarbose in diabetes mellitus: a critical review of controlled trials. Diabetes Metab 1998 ; 24 : 311-20.
20. Fischer S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998 ; 44 : 34-40.